Glooko announces the addition of Tracy Bahl and Mike Doherty as Independent Members of the Board
MOUNTAIN VIEW, Calif, Aug 12, 2020 – As Glooko continues its journey to transform digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration, today they announced the addition of Tracy Bahl and Mike Doherty as independent members of the Board of Directors to provide guidance and support to the continued growth of the business.
“We are very excited to welcome Mike and Tracy to Glooko,” says Russ Johannesson, CEO at Glooko. “We are proud of our distinguished and active board of directors and Tracy and Mike will complement them with their extensive experience. From the start, Glooko has been dedicated to making the lives of people with diabetes easier, and I am convinced that the addition of our new members will add tremendous value supporting our rapid growth in telehealth and clinical research, in both existing and new geographies.”
Bahl, with an extensive background in senior leadership roles at healthcare companies such as CVS Health and UnitedHealth Group, brings expertise in health plan growth and operations, revenue cycle management and healthcare services. As Glooko expands its global provider footprint and partners with payers and employers, Bahl will be tapped for his expertise and guidance.
“I’m thrilled about the opportunity to join Glooko as a board member and be part of this exciting journey”, Bahl said. “This company provides a unique value proposition for patients, providers and payers, and I see a huge potential for Glooko’s services in support of remote care and remote patient monitoring. With the COVID-19 pandemic, which has affected us all, we’ve seen the need and value of telehealth has grown immensely. As we head into the new normal, Glooko can really make a difference by enabling collaboration and remote care in healthcare.”
Doherty joins Glooko’s board with an in-depth knowledge and experience in regulatory affairs, pharmaceutical development, data strategy and clinical research, from a distinguished career in global companies such as AstraZeneca, Roche and Foundation Medicine where he held a variety of senior leadership roles. With Glooko’s focus on enabling virtual clinical studies and global expansion into new markets, Doherty’s experience is particularly valuable.
“I am excited to be part of Glooko’s board of directors”, Doherty said. “I see a great potential for Glooko to add value in the field of clinical research and real world data by enabling clinical trials globally. I look forward to contributing to the global expansion of this exciting company as it transitions into its next phase of growth.”
Glooko is transforming digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration.
The company’s software platforms, Glooko® and diasend®, empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers – bringing insights together in one place.
Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice.
2.8 million users have benefited from diabetes data insights using Glooko’s solutions, which are trusted by world leaders in diabetes care, and used in 26 countries across 15 languages. Learn more at glooko.com.